Capital Raising through Private Placement and Public Offering
First written in FY2022-Q3. 1 of 8 entries say "Advanced", first in FY2022-Q3. Latest entry: FY2026-H1.
2 other companies' latest entry also says "Other".
- FY2026-H1The number of shares outstanding continues to increase through the exercise of stock acquisition rights and restricted stock compensationAnnual report
「Following a resolution of the Board of Directors meeting held on 27 June 2025, new shares were issued as restricted stock compensation on 18 July 2025, increasing total shares outstanding by 37,372 and share capital and capital reserves by ¥11,006,054 each.」
During the current interim consolidated accounting period, 60,000 shares were added through the exercise of stock acquisition rights, and 37,372 shares were issued as restricted stock compensation. Before the filing date, a further 26,000 shares were added through the exercise of stock acquisition rights. - FY2025Continued increase in shares through the exercise of stock acquisition rights and share-based compensationAnnual report
「Part of the increase in shares outstanding resulted from the exercise of stock acquisition rights (1,995,343 shares), increasing share capital and capital surplus by ¥76.152 million each.」
During the fiscal year, 1,995,343 shares were added through the exercise of stock acquisition rights, and 23,999 shares were also issued as restricted stock compensation. - FY2025-H1The number of shares outstanding continues to increase through the exercise of stock acquisition rights and restricted stock compensationAnnual report
「1 April 2024–30 September 2024 Resulting from the exercise of stock acquisition rights.」
During the current interim consolidated accounting period, 200,000 shares were added through the exercise of stock acquisition rights, and 23,999 shares were issued as restricted stock compensation. Before the filing date, stock acquisition rights for a further 2,000 shares were exercised in October 2024. - FY2024-Q3Continued increase in shares through the exercise of stock acquisition rightsAnnual report
「Between 1 January 2024 and 31 January 2024, the total number of shares outstanding increased by 225,000 through the exercise of stock acquisition rights.」
The exercise of stock acquisition rights continued after the quarter-end, increasing shares outstanding by 225,000 during January 2024. The company also reported the exercise of stock acquisition rights for 111,000 shares during the cumulative quarter. - FY2024-Q2Continued issuance of shares through the exercise of stock acquisition rights and share-based compensationAnnual report
「Part of the increase in shares outstanding resulted from the exercise of stock acquisition rights (63,000 shares), which increased share capital and capital surplus by ¥2.475 million each during the cumulative second-quarter consolidated period.」
During the cumulative second-quarter consolidated period, stock acquisition rights for 63,000 shares were exercised, increasing share capital and capital surplus by ¥2.475 million each. The company also reported the issuance of 23,998 shares as restricted stock compensation. - FY2024-Q1Continued issuance of shares through the exercise of stock acquisition rights and share-based compensationAnnual report
「The increase in shares outstanding resulted from the exercise of stock acquisition rights (12,000 shares), which increased share capital and capital surplus by ¥525,000 each during the cumulative first-quarter consolidated period.」
During the first quarter, stock acquisition rights for 12,000 shares were exercised. As of the filing date, 23,998 shares had also been issued as restricted stock compensation. - FY2023-Q3Increase in shares through the exercise of stock acquisition rights and share-based compensationAnnual report
「Part of the increase in shares outstanding resulted from the exercise of stock acquisition rights (192,000 shares), which increased share capital and capital surplus by ¥7.275 million each during the cumulative nine-month consolidated period. Another part resulted from the issuance of new shares as restricted stock compensation (17,287 shares).」
During the cumulative nine-month consolidated period, stock acquisition rights were exercised and new shares were issued as restricted stock compensation, increasing the number of shares outstanding. - FY2022-Q3AdvancedAnnual report
「In connection with the listing, the company issued 1,400,000 new domestic shares and 2,600,000 new overseas shares, increasing share capital by ¥2,757 million and capital surplus by ¥2,727 million.」
In addition to issuing new shares in connection with the listing, the company conducted a private placement and exercised stock acquisition rights, thereby increasing capital.